Visiongain has published a new report on Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab, Cetuximab, Follitropin Alfa, Somatropin, Dornase Alfa). PLUS, Regional Market Analysis AND COVID-19 Recovery Scenarios.

Top 50 Biosimilar Companies Report– Read on to determine how you can exploit the impending business opportunities emerging in this sector along with profile of top 50 companies operating in the market.

The global biosimilars market is projected to reach at a market value of USxx billion by 2023 with a lucrative CAGR during the forecast period. Visiongain’s report shows you the potential revenues streams to 2023, assessing the top 20 products, the major 50 key players, qualitative analysis, opportunities trends, and business prospects in the biosimilars industry.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/top-50-biosimilar-drug-manufacturers-2021/#download_sampe_div

The company profiles are divided into three segments including:

Major Players: Profiles of major 15 companies that account for over 60% market share in the global biosimilars market
Mid-Range Players: Profiles of 20 pioneering companies that account for significant market share and focuses on the innovative strategic collaborations and M&A
Ones to Watch – New Players: Profiles of 15 growing companies that are investing a huge amount of money in biosimilars R&D and focuses on new drug development
Global market revenue and growth forecasts from 2020 to 2023 by product
The global biosimilars market revenue will surpass $16.57 billion in 2020 with a lucrative CAGR during the forecast period 2021-2023 to reach significant revenue growth to 2023.

The major product considered in the report are:

Adalimumab
Etanercept
Trastuzumab
Infliximab
Insulin Glargine
Rituximab
Pegfilgrastim
Epoetin Alfa
Teriparatide
Bevacizumab
Insulin Lispro
Darbepoetin Alfa
Filgrastim
Enoxaparin
Eculizumab
Natalizumab
Cetuximab
Follitropin Alfa
Somatropin
Dornase Alfa
Other Biosimilars

Leading Companies Profiled in this Report include:

AbbiVie
Alvotech
Amgen
Apotex/Apobiologix
Aryogen
Aurobindo Pharma
Avesthagen Ltd.
Biocon
Biogen
Boehringer Ingelheim
Celltrion
Cipla
Coherus BioSciences, Inc.
Daiichi Sankyo Company Ltd
Dr. Reddy's
Egis Pharmaceuticals PLC
Eli Lilly
Formycon
Fresenius Kabi
Fujifilm Kyowa Kirin Biologics
Gedeon Richter
Gene Techno Science
Generium
Harvest Moon Pharma
Hetero
Intas Pharmaceuticals Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Kashiv Pharma
Ligand Pharmaceuticals
Lupin
Mabion
Merck & Co.
Mochida
Mundipharma Biologics
Mylan
Nichi-iko
Pfizer
PolPharma
Reliance Life Sciences
Samsung Bioepis
Sandoz -Novartis
Sanofi
Shenzhen Techdow Pharmaceutical
STADA Arzneimittel AG
Teva
Torrent Pharma
USV BIOLOGICS
Xbrane
Zhejiang Hisun Pharma
Zydus Cadila

Get Detailed TOC @ https://www.visiongain.com/report/top-50-biosimilar-drug-manufacturers-2021/#download_sampe_div

How this report will benefit you
Visiongain’s new study is envisioned for anyone requiring commercial in-depth analyses for the global biosimilars market along with detailed company profiles of top 50 companies operating in the market. Our new study assists you to evaluate the overall global and regional market for biosimilars. Get the financial analysis of the overall market and major 50 player’s revenue predictions till 2023. High opportunity remains in this fast-growing Biosimilars Market. See how to exploit the existing opportunities in the market to gain maximum advantage in the near future.

In summary, this 372-page report delivers with the following knowledge:

Revenue forecasts from 2020 to 2023 for the global biosimilars market and sub segments (by products and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
Detailed profiles of Top 50 Biosimilar Companies, with financial forecasts for net revenues, operating income, R&D investment, and biosimilar segment revenue
Revenue forecasts from 2020 to 2023 for 5 regional markets – See forecasts for the biosimilars market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email [email protected]

Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global Biosimilars market and Detailed Analysis of 50 Leading Companies. You will get the most recent data, opportunities, trends, and predictions.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.